This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Human medicines European public assessment report (EPAR): Paxlovid, nirmatrelvir...
Opinion/decision on a Paediatric investigation plan (PIP): Enerzair Breezhaler, ...
Human medicines European public assessment report (EPAR): Zinforo, ceftaroline f...
Human medicines European public assessment report (EPAR): Karvea, irbesartan, Da...
Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts ha...
Opinion/decision on a Paediatric investigation plan (PIP): Skyrizi, Risankizumab...
Human medicines European public assessment report (EPAR): Beyfortus, nirsevimab,...
After its depression candidate failed a phase 3 trial and disappointed analysts,...
Human medicines European public assessment report (EPAR): Fasenra, benralizumab,...
Astellas is shifting its investment focus toward more established modalities and...
Union list of critical medicines: eXtended EudraVigilance Medicinal Product Dict...
Reports of impending layoffs, a buyout offer, and a return-to-office mandate hav...
Herbal medicinal product: Anisi aetheroleumArray, C: ongoing call for scientific...
Herbal medicinal product: Valerianae radixArray, C: ongoing call for scientific ...
Herbal medicinal product: Valerianae aetheroleumArray, C: ongoing call for scien...
Herbal medicinal product: Salviae officinalis foliumArray, C: ongoing call for s...
Herbal medicinal product: Centaurii herbaArray, C: ongoing call for scientific data
Herbal medicinal product: Anisi fructusArray, C: ongoing call for scientific data
Herbal medicinal product: Hyperici herbaArray,Array, D: Draft under discussion